Prof. Dr. İsmail ERTÜRK

1. Clinical characteristics and survival outcomes of adult inflammatory myofibroblastic tumor: a retrospective single-center study

Dumludağ A., Yıldırım G., Topal A., Tüzün E. K., Karadurmuş B., ERTÜRK İ., et al.

Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

2. Clinical significance of CD27+CD28+ effector memory T cells as potential prognostic biomarkers in ovarian cancer

Uluturk S., Aras I. A., Altahhan V., Sakar V., Karadurmus B., Hidiroglu M. M., et al.

Journal of Ovarian Research , cilt.19, sa.1, 2026 (SCI-Expanded, Scopus)

3. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

Kıkılı C. İ., Araz M., ÜRÜN Y., BAŞARAN M., Şener N., Yazar A., et al.

Clinical Genitourinary Cancer , cilt.24, sa.5, 2026 (SCI-Expanded, Scopus)

4. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Seyyar M., Kalem A., Sali M., Karabuğa B., ŞAHİN T. K., Dişli A. K., et al.

Current Oncology , cilt.33, sa.6, 2026 (SCI-Expanded, Scopus)

5. Pre-Transplant Prognostic Nutritional Index Independently Predicts Progression-Free Survival After Autologous Stem Cell Transplantation in Lymphoma

Atacan H., Aslan V., Topal A., Mammadzada N., Yıldırım G., Güneysu G. G., et al.

Journal of Clinical Medicine , cilt.15, sa.9, 2026 (SCI-Expanded, Scopus)

6. Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model

YILMAZ K. B., TAVUKÇUOĞLU DEMİR E., YANIK H., Seçken P., ÇELİK E., Guler S., et al.

Medicina (Lithuania) , cilt.62, sa.3, 2026 (SCI-Expanded, Scopus)

7. Assessment of Meet-URO and CANLPH Prognostic Models in Metastatic RCC: Insights from a Single-Institution Cohort Predominantly Treated with TKIs

Kuzu Ö. F., KARADURMUŞ N., Kanat N. B., Özel Bozdağ D. İ., Karadurmuş B., Kaplan Tüzün E., et al.

Diagnostics , cilt.16, sa.3, 2026 (SCI-Expanded, Scopus)

8. The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancer

Bilgetekin I., Demirci U., Yildirim H. C., Dogan M., Karacin C., Onur İ. D., et al.

Clinical and Translational Oncology , 2026 (SCI-Expanded, Scopus)

9. Comparison of Third-Line Treatment Options in Patients with Metastatic Renal Cell Carcinoma

Kuzu Ö. F., Kanat N. B., Bozdağ D. İ. Ö., Topal A., KARADURMUŞ N., ERTÜRK İ.

Acta Haematologica Oncologica Turcica , cilt.58, sa.3, ss.202-205, 2025 (Scopus, TRDizin)

10. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

ŞENDUR M. A. N., Hizal M., Çakar B., AKTEPE O. H., Eraslan E., ARIK Z., et al.

BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

11. Evaluation of the Efficacy and Safety of FOLFOX in First-Line Treatment of Advanced Pancreatic Cancer

Atacan H., Yildiran Keski̇n G. S., Emi̇n G., Kahraman S., Mammadzade N., Yildirim G., et al.

Journal of Oncological Science , cilt.11, sa.3, ss.211-216, 2025 (Scopus, TRDizin)

12. The Efficacy of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Ewing Sarcoma Patients

Kuzu Ö. F., KARADURMUŞ N., Kanat N. B., Köseoğlu Ç., Dumludağ A., Topal A., et al.

Journal of Clinical Medicine , cilt.14, sa.24, 2025 (SCI-Expanded, Scopus)

13. Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

İşleyen Z. S., Ay S., BAYRAM E., Seçmeler Ş., Selvi O., Kılıçkap S., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

14. The Impact of Clinical and Morphometric Parameters on Hematopoietic Engraftment Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Germ Cell Tumors

Kuzu Ö. F., KARADURMUŞ N., Acar A. G., Kanat N. B., Köseoğlu Ç., Dumludağ A., et al.

Medicina (Lithuania) , cilt.61, sa.9, 2025 (SCI-Expanded, Scopus)

15. Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey

Yildiran Keskin G. S., YETGİNOĞLU Ö., VURĞUN S., Guzel E. Z., Ozkan F. E., Yilmaz M., et al.

Medicina (Lithuania) , cilt.61, sa.6, 2025 (SCI-Expanded, Scopus)

16. “Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?

Yaşar S., Kadıoğlu A., Akyildiz A., Sever N., Büyükbayram M. E., BİLİCİ M., et al.

Medicina (Lithuania) , cilt.61, sa.6, 2025 (SCI-Expanded, Scopus)

17. Efficacy and Safety of Three Cycles of TIP and Sequential High Dose Chemotherapy in Patients with Testicular Non-Seminomatous Germ Cell Tumors

AYKAN M. B., Yildiran Keskin G., ERTÜRK İ., Acar R., Kose A. F., KARADURMUŞ N.

Journal of Clinical Medicine , cilt.14, sa.1, 2025 (SCI-Expanded, Scopus)

18. TROP-2 expression in triple-negative and human epidermal growth factor receptor 2 enriched breast cancers and its relationship with clinicopathologic parameters

Kivrak H., Simsek D. T., AKINCIOĞLU E., Seçinti İ. E., Keskin G. S. Y., ERTÜRK İ., et al.

Polish Journal of Pathology , cilt.76, sa.3, ss.248-256, 2025 (SCI-Expanded, Scopus)

19. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

Dülgar Ö., Türker S., BAŞARAN G., Araz M., Sümbül A. T., Çağlayan D., et al.

Journal of Chemotherapy , cilt.37, sa.4, ss.334-340, 2025 (SCI-Expanded, Scopus)

20. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

Beypınar İ., Demir H., YASLIKAYA Ş., KÖŞECİ T., Demir B., Çolak G., et al.

Breast Cancer Research and Treatment , cilt.208, sa.3, ss.597-604, 2024 (SCI-Expanded, Scopus)

21. Salvage Treatment for Extragonadal Germ Cell Tumours: High-Dose Chemotherapy and Autologous Stem Cell Transplantation Outcomes—A Single-Centre Experience

Topal A., ERTÜRK İ., Koseoglu C., Dumludag A., Kuzu Ö. F., Karadurmus B., et al.

Journal of Clinical Medicine , cilt.13, sa.21, 2024 (SCI-Expanded, Scopus)

22. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

Karci E., BİLİCİ A., Bayram B., Celayir M., Ozyurt N., OYAN ULUÇ B., et al.

Cancers , cilt.16, sa.19, 2024 (SCI-Expanded, Scopus)

23. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?

OCAK B., ŞAHİN A. B., ERTÜRK İ., Korkmaz M., Erdem D., Cakıroglu U., et al.

Current Oncology , cilt.31, sa.9, ss.5195-5205, 2024 (SCI-Expanded, Scopus)

24. The Role of High Dose Chemotherapy with Autologous Hematopoietic Cell Transplant in Relapsed/Refractory Ovarian Germ Cell Tumors: A Single Center Experience

Topal A., ERTÜRK İ., Koseoglu C., Dumludag A., Kuzu Ö. F., Durmaz P., et al.

Clinical Genitourinary Cancer , cilt.22, sa.4, 2024 (SCI-Expanded, Scopus)

25. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience

Yildiran Keskin G. S., ERTÜRK İ., AYKAN M. B., Acar R., Dumludag A., Topal A., et al.

Oncology Research and Treatment , cilt.47, sa.6, ss.262-272, 2024 (SCI-Expanded, Scopus)

26. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer

Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., ERSOY M., et al.

Future Oncology , cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded, Scopus)

27. Efficacy of Perioperative FLOT Therapy in Locally Advanced Gastric Cancer and the Associated Prognostic Factors

Yildiran Keskin G. S., ERTÜRK İ., AYKAN M. B., Acar R., Topal A., Dumludağ A., et al.

Journal of Oncological Science , cilt.10, sa.2, ss.97-104, 2024 (Scopus, TRDizin) Sürdürülebilir Kalkınma

28. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., Keskinkılıç M., Baytemür N. K., Yılmaz F., et al.

BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded, Scopus)

29. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

Akyildiz A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., ÜNAL O. Ü., et al.

Medicine (United States) , cilt.102, sa.45, 2023 (SCI-Expanded, Scopus)

30. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Hizal M., Bilgin B., Paksoy N., Atcı M. M., Kahraman S., Kılıçkap S., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.8, ss.4141-4148, 2023 (SCI-Expanded, Scopus)

31. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

Erol C., YEKEDÜZ E., Tural D., KARAKAYA S., Şentürk Öztaş N., Uçar G., et al.

Urologia Internationalis , cilt.107, sa.6, ss.595-601, 2023 (SCI-Expanded, Scopus)

32. Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkish oncology group study

Acar R., PAYDAŞ S., YILDIRIM M., Kiliçarslan E., ŞAHİN U., DOĞAN A. A., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.8, 2023 (SCI-Expanded, Scopus)

33. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

YEKEDÜZ E., KARAKAYA S., ERTÜRK İ., Tural D., Uçar G., Şentürk Öztaş N., et al.

Clinical Genitourinary Cancer , cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus)

34. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

YEKEDÜZ E., Tural D., ERTÜRK İ., KARAKAYA S., Erol C., Ercelep Ö., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3537-3546, 2022 (SCI-Expanded, Scopus)

35. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded, Scopus)

36. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Yücel K. B., YEKEDÜZ E., KARAKAYA S., Tural D., ERTÜRK İ., Erol C., et al.

Scientific Reports , cilt.12, sa.1, 2022 (SCI-Expanded, Scopus)

37. Efficacy of ifosfamide, carboplatin and etoposide chemotherapy protocol in relapsed refractory germ cell tumors

AYKAN M. B., ERTÜRK İ., Acar R., Keskin G. S., Örnek E., KARADURMUŞ N.

Gulhane Medical Journal , cilt.64, sa.3, ss.229-234, 2022 (Scopus, TRDizin)

38. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Hizal M., Bilgin B., Paksoy N., Klllçkap S., Atcl M. M., Kahraman S., et al.

Future Oncology , cilt.18, sa.23, ss.2573-2582, 2022 (SCI-Expanded, Scopus)

39. Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours

AYKAN M. B., Yildiran G. S., Akcan E., Acar R., ERTÜRK İ., KARADURMUŞ N.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.7, ss.880-884, 2022 (SCI-Expanded, Scopus)

40. The assessment of rheumatologic immune-related adverse events with immune checkpoint inhibitors

TEKGÖZ E., Colak S., Acar R., ERTÜRK İ., AYKAN M. B., Yıldız B., et al.

Gulhane Medical Journal , cilt.64, sa.1, ss.103-109, 2022 (Scopus, TRDizin)

41. High-dose Chemotherapy Response in Adults with Relapsed/Refractory Small Round Cell Tumours

AYKAN M. B., ERTÜRK İ., Acar R., Yildiran G. S., Yildiz B., KARADURMUŞ N.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.1, ss.51-56, 2022 (SCI-Expanded, Scopus)

42. Retrospective Analysis of Testicular Germ Cell Tumor Patients with Brain Metastases: A Single-Center Experience

AYKAN M. B., Yildiran G. S., Acar R., Igret N., Yildiz B., ERTÜRK İ., et al.

Journal of Oncological Science , cilt.8, sa.1, ss.27-33, 2022 (Scopus, TRDizin)

43. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

YEKEDÜZ E., ERTÜRK İ., Tural D., KARADURMUŞ N., KARAKAYA S., Hlzal M., et al.

Future Oncology , cilt.17, sa.35, ss.4861-4869, 2021 (SCI-Expanded, Scopus)

44. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Karacin C., EREN T., Zeynelgil E., İMAMOĞLU G. İ., ALTINBAŞ M., KARADAĞ İ., et al.

Future Oncology , cilt.17, sa.33, ss.4447-4456, 2021 (SCI-Expanded, Scopus)

45. Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation

ERTÜRK İ., KARADURMUŞ N., Kızıloz H., ACAR R., YILDIZ B., AYKAN M. B., et al.

Journal of Oncology Pharmacy Practice , cilt.27, sa.7, ss.1657-1664, 2021 (SCI-Expanded, Scopus)

46. Clinical presentation and course of the novel coronavirus disease 2019 in patients with various types of cancer: A retrospective case-control analysis of an experienced cancer center in Turkey

Acar R., YILMAZ TEHLİ G., SAVAŞÇI Ü., AYKAN M. B., Kiziloz H., CÜCE F., et al.

Journal of Cancer Research and Therapeutics , cilt.17, sa.2, ss.556-564, 2021 (SCI-Expanded, Scopus)

47. Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer

Bilgetekin I., ERTÜRK İ., Basal F. B., Karacin C., KARADURMUŞ N., Oksuzoglu B., et al.

International Urology and Nephrology , cilt.53, sa.2, ss.301-307, 2021 (SCI-Expanded, Scopus)

48. Effectiveness of bendamustine in relapsed or refractory lymphoma cases: A Turkish oncology group study

KARADURMUŞ N., PAYDAŞ S., Esin E., Surmeli Z. G., Yildiz B., ERTÜRK İ., et al.

Archives of Medical Science , cilt.17, sa.4, ss.920-927, 2021 (SCI-Expanded, Scopus)

49. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥ 75) patients

Alkan A., Güç Z. G., Gürbüz M., Özgün G., Değirmencioğlu S., DOĞAN M., et al.

Journal of Men's Health , cilt.17, sa.4, ss.128-134, 2021 (SCI-Expanded, SSCI, Scopus)

50. Retrospective analysis of patients with relapsed/refractory medulloblastoma after autologous stem cell transplantation

Acar R., ERTÜRK İ., Kizilöz H., Okçelik S., Yildiz B., AYKAN M. B., et al.

Gulhane Medical Journal , cilt.62, sa.4, ss.266-271, 2020 (Scopus, TRDizin)

51. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

Hizal M., Sendur M. A., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1583-1589, 2020 (SCI-Expanded, Scopus)

52. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., KARAKAYA S., Bilgin B., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.5, ss.1110-1116, 2020 (SCI-Expanded, Scopus)

53. What is the optimal high-dose treatment following autologous stem cell transplantation in relapsed or refractory germ cell cancer: A retrospective comparison of high-dose ICE and highdose CE

Yildiz B., Aral I. P., Balyemez U., Esin E., ERTÜRK İ., Acar R., et al.

Journal of B.U.ON. , cilt.25, sa.2, ss.1136-1140, 2020 (SCI-Expanded, Scopus)

54. Does primary tumor localization has prognostic importance in seminoma patients?: Turkish oncology Group study

Yildiz B., KÜÇÜKARDA A., Gokyer A., Demiray A. G., PAYDAŞ S., Aral I. P., et al.

Journal of B.U.ON. , cilt.25, sa.2, ss.1130-1135, 2020 (SCI-Expanded, Scopus)

55. Autologous stem cell transplantation in patients with extragonadal germ cell tumors: A single center experience

Yildiz B., Aral I. P., BAŞGÖZ B. B., ERTÜRK İ., Acar R., KARADURMUŞ N.

Gulhane Medical Journal , cilt.62, ss.97-102, 2020 (Scopus, TRDizin)

56. Gemcitabine, oxaliplatin and paclitaxel (Gempox) in patients with relapsed or refractory germ cell tumors after high dose chemotherapy, a retrospective single-center experience

Acar R., ERTÜRK İ., Kiziloz H., Okcelik S., Yildiz B., AYKAN M. B., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.30, sa.4, ss.191-196, 2020 (SCI-Expanded, Scopus, TRDizin)

57. Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with preserved ejection fraction via VEGF and sVEGFR-1

ERTÜRK İ., SERTOĞLU E., Bilgi C., SAĞLAM K., YEŞİLDAL F., Acar R., et al.

Turkish Journal of Biochemistry , cilt.44, sa.1, ss.25-31, 2019 (SCI-Expanded, Scopus, TRDizin)

58. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Esin E., Oksuzoglu B., BİLİCİ A., Cicin I., KÖSTEK O., Kaplan M., et al.

Cancer Chemotherapy and Pharmacology , cilt.83, sa.1, ss.131-143, 2019 (SCI-Expanded, Scopus)

59. Angiostatin levels in systolic heart failure patients with chronic kidney disease

ERTÜRK İ., SERTOĞLU E., ÖZGÜRTAŞ T., YEŞİLDAL F., Acar R., Yildiz B., et al.

International Journal of Medical Biochemistry , cilt.2, sa.2, ss.41-45, 2019 (Scopus, TRDizin)

60. Evaluation of plasma VEGF and sVEGFR-1 levels in patients with diabetes mellitus receiving insulin treatment

ERTÜRK İ., SERTOĞLU E., YEŞİLDAL F., Acar R., SAĞLAM K., ÖZGÜRTAŞ T.

Turkish Journal of Biochemistry , cilt.44, sa.2, ss.182-188, 2019 (SCI-Expanded, Scopus, TRDizin)

61. Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with reduced/mid-range ejection fraction via vegf and svegfr-1

ERTÜRK İ., SAĞLAM K., Elasan S., AYKAN M. B., Acar R., YEŞİLDAL F., et al.

Saudi Medical Journal , cilt.39, sa.10, ss.1028-1034, 2018 (SCI-Expanded, Scopus)

62. Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with endstage renal disease: Associations with laboratory findings, comorbidities, and medications

ERTÜRK İ., YEŞİLDAL F., Acar R., ÖZGÜRTAŞ T., SAĞLAM K.

Saudi Medical Journal , cilt.39, sa.6, ss.586-591, 2018 (SCI-Expanded, Scopus)

63. Angiostatin levels in diabetes mellitus patients receiving insulin treatment: Associations with laboratory findings, comorbidities, and medications

ERTÜRK İ., SERTOĞLU E., YEŞİLDAL F., Acar R., ÖZGÜRTAŞ T., SAĞLAM K.

Turkish Journal of Medical Sciences , cilt.48, sa.6, ss.1192-1199, 2018 (SCI-Expanded, Scopus, TRDizin)

64. Retrospective analysis of long-term survival after combination treatment with gemcitabine, oxaliplatin and paclitaxel in patients with refractory or relapsed testicular cancers

ERTÜRK İ., Yildiz B., KARADURMUŞ N., TOSUN B., Esen R., Acar R., et al.

Gulhane Medical Journal , cilt.60, sa.4, ss.145-150, 2018 (Scopus, TRDizin)

65. Retrospective analysis of patients with relapsed or refractory germ cell tumors treated with autologous hematopoietic stem cell transplantation

ERTÜRK İ., Yildiz B., KARADURMUŞ N., TOSUN B., Esen R., Sürmeli Z. G., et al.

Gulhane Medical Journal , cilt.60, sa.4, ss.130-135, 2018 (Scopus, TRDizin)

66. A case report: Primary amiloidosis associated with immunoglobulin A type multiple myeloma

KARADURMUŞ N., ERTÜRK İ., Çakar M., Altun B., SAĞLAM K., Arpaci F.

Respiratory Medicine CME , cilt.4, sa.3, ss.131-132, 2011 (Scopus)

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Proje

Tez Danışmanlığı

Açık Erişim